United States, Jan. 29 -- GE HealthCare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MIM LesionID (TM) Pro, an innovative solution from its MIM software portfolio that transforms whole-body tumor burden analysis for PSMA PET/CT and SPECT/CT studies into a significantly simplified process. Designed in collaboration with leading theranostics practitioners, MIM LesionID Pro features intuitive, user-friendly tools and AI-powered automation aimed at making whole-body tumor burden analysis more feasible to incorporate into routine clinical practice-to ultimately reduce physician effort in obtaining patient-specific insights to aid in confident decision-making.Theranostics is a personalized approach in nuclear...